TLRY Tilray Brands (TLRY) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001731348
Cluster · 3 insidersC-suite buying · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
109
13F, latest reported quarter
Conversions, 180 days
22
Codes C/M, not in net · $0 priced
What the filings say about TLRY
Insiders, 180 days
+$69.2K net bought
3 buyers
Tilray Brands insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Tilray Brands, Inc. insiders bought a net $69.2K of stock across 23 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 31, 2025.
- +1.6% median (+40.4% mean) 90-day return after 3 previous buys.
- The trade is 2.0% of the 124,883 shares held after it.
- 2 other insiders bought within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Global General Counsel Gendel Mitchell bought about $11.1K of TLRY on Aug 6, 2026; 2 other insiders bought within 30 days and 109 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 30, 2025.
- +1.6% median (+32.5% mean) 90-day return after 3 previous buys.
- The trade is 7.2% of the 139,753 shares held after it.
- 2 other insiders bought within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Merton Carl A bought about $46.2K of TLRY on Aug 4, 2026, the largest insider purchase at the company since 2025; 2 other insiders bought within 30 days and 109 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 17, 2024.
- The trade is 1.8% of the 141,285 shares held after it.
- 2 other insiders bought within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Strategy Officer FALTISCHEK DENISE M bought about $11.9K of TLRY on Aug 3, 2026, the largest insider purchase at the company since 2025; 2 other insiders bought within 30 days and 109 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- No other insider sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hopkinson David G. sold about $232.9K of TLRY on Apr 21, 2026, the largest insider sale at the company since 2022; 109 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jan 16, 2024.
- -6.6% median (-6.6% mean) 90-day return after 2 previous buys.
- The trade is 0.9% of the 698,287 shares held after it.
- 2 other insiders bought within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Global General Counsel Gendel Mitchell bought about $3.5K of TLRY on Jul 31, 2025; 2 other insiders bought within 30 days and 109 funds added in the latest 13F quarter.23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$69.2K over 180 days
+$69.2K over 90 days
more than 74% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
109 funds bought in last quarter
more than 72% of Pharma & Biotech
Revenue
+11.5% year over year
more than 61% of Pharma & Biotech
Margin
-13.3% net margin
more than 62% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.8% of the float short (float per yahoo 2026-10-26) · 5.2 days to cover · settled 2026-09-30
more than 80% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 insiders independently bought a net $69.2K while the stock fell 60% over six months, with no planned sales queued.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TLRY
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-81.3%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TLRY: institutional holders (13F)
13F holdings, latest reported quarter
2,498,656 sh
$11.2M
1,021,777 sh
$4.6M
995,145 sh
$4.5M
868,147 sh
$3.9M
648,506 sh
$2.9M
Congress trades in TLRY
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TLRY planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TLRY mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Amplify Alternative Harvest ETF
$11.1M position · as of 2026-06-30
10.0%
AdvisorShares Pure Cannabis ETF
$342.4K position · as of 2026-06-30
1.0%
The Free Markets ETF
$98.1K position · as of 2026-05-31
0.7%
Sofi Social 50 ETF
$49.8K position · as of 2026-05-31
0.1%
Lazard US Systematic Small Cap Equity ETF
$76.6K position · as of 2026-06-30
0.1%
Innovator U.S. Small Cap Managed 10 Buffer ETF
$4.8K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $69.2K bought by insiders over 180 days, 109 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TLRY financials
Revenue growth
+11.5%
XBRL, annual
Net margin
-13.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$963.1M
four quarters, 2025-09-01 to 2026-08-31
Revenue, TTM TLRY
| FY May 2026 | $915.5M |
| FY May 2025 | $821.3M |
| FY May 2024 | $788.9M |
| FY May 2023 | $627.1M |
| FY May 2022 | $628.4M |
| Aug 2026 | $257.1M |
| May 2026 | $281.7M |
| Feb 2026 | $206.7M |
| Nov 2025 | $217.5M |
| Aug 2025 | $209.5M |
| May 2025 | $224.5M |
| Feb 2025 | $185.8M |
| Nov 2024 | $210.9M |
At each fiscal year end
Single quarter
Net margin, TTM
-17.1%
net income over revenue, 2025-09-01 to 2026-08-31
Net margin, TTM TLRY
| FY May 2026 | -13.3% |
| FY May 2025 | -266.3% |
| FY May 2024 | -31.1% |
| FY May 2023 | -231.6% |
| FY May 2022 | -75.9% |
| Aug 2026 | -16.8% |
| May 2026 | -17.6% |
| Feb 2026 | -12.9% |
| Nov 2025 | -20.7% |
| Aug 2025 | -0.2% |
| May 2025 | -566.9% |
| Feb 2025 | -424.9% |
| Nov 2024 | -40.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$117.3M
operating cash flow minus capex, 2025-09-01 to 2026-08-31
Free cash flow, TTM TLRY
| FY May 2026 | -$102.1M |
| FY May 2025 | -$127.5M |
| FY May 2024 | -$60.2M |
| FY May 2023 | -$12.9M |
| FY May 2022 | -$211.3M |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | -$19.1M |
| Feb 2025 | -$20.2M |
| Nov 2024 | -$46.2M |
At each fiscal year end
Single quarter
Debt to equity
0.08x
long-term 2026-08-31 plus current 2026-08-31; equity 2026-08-31
Debt to equity TLRY
| FY May 2026 | 0.08x |
| FY May 2025 | 0.06x |
| FY May 2024 | 0.04x |
| FY May 2023 | 0.07x |
| FY May 2022 | 0.04x |
| Aug 2026 | 0.08x |
| May 2026 | 0.08x |
| Feb 2026 | 0.06x |
| Nov 2025 | 0.06x |
| Aug 2025 | 0.06x |
| May 2025 | 0.06x |
| Feb 2025 | 0.04x |
| Nov 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.67x
TTM operating cash flow over long-term 2026-08-31 plus current 2026-08-31
Cash flow to debt TLRY
| FY May 2026 | -0.54x |
| FY May 2025 | -1.01x |
| FY May 2024 | -0.21x |
| FY May 2023 | 0.03x |
| FY May 2022 | -0.95x |
| Aug 2026 | -0.67x |
| May 2026 | -0.54x |
| Feb 2026 | -0.46x |
| Nov 2025 | -0.30x |
| Aug 2025 | -0.66x |
| May 2025 | -1.01x |
| Feb 2025 | -0.44x |
| Nov 2024 | -0.43x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-10.4%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on equity TLRY
| FY May 2026 | -7.8% |
| FY May 2025 | -88.3% |
| FY May 2024 | -7.2% |
| FY May 2023 | -37.7% |
| FY May 2022 | -10.8% |
| Aug 2026 | -10.4% |
| May 2026 | -7.8% |
| Feb 2026 | -63.1% |
| Nov 2025 | -83.4% |
| Aug 2025 | -85.6% |
| May 2025 | -88.3% |
| Feb 2025 | -31.2% |
| Nov 2024 | -7.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-7.4%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on assets TLRY
| FY May 2026 | -5.5% |
| FY May 2025 | -69.5% |
| FY May 2024 | -5.7% |
| FY May 2023 | -29.8% |
| FY May 2022 | -8.3% |
| Aug 2026 | -7.4% |
| May 2026 | -5.5% |
| Feb 2026 | -64.8% |
| Nov 2025 | -67.0% |
| Aug 2025 | -67.7% |
| May 2025 | -69.5% |
| Feb 2025 | -24.8% |
| Nov 2024 | -5.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital TLRY
| FY May 2026 | n/a |
| FY May 2025 | n/a |
| FY May 2024 | n/a |
| FY May 2023 | n/a |
| FY May 2022 | n/a |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-4.8%
operating income (EBIT proxy) over average of 2025-08-31 and 2026-08-31 minus current liabilities
Return on capital employed TLRY
| FY May 2026 | -3.3% |
| FY May 2025 | -79.9% |
| FY May 2024 | -4.5% |
| FY May 2023 | -30.3% |
| FY May 2022 | -11.3% |
| Aug 2026 | -4.8% |
| May 2026 | -3.3% |
| Feb 2026 | -82.0% |
| Nov 2025 | -77.3% |
| Aug 2025 | -77.6% |
| May 2025 | -79.9% |
| Feb 2025 | -24.2% |
| Nov 2024 | -4.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TLRY
| FY May 2026 | n/a |
| FY May 2025 | n/a |
| FY May 2024 | n/a |
| FY May 2023 | n/a |
| FY May 2022 | n/a |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$321.1M
market value at close 2026-10-27 on 2026-10-06 shares, plus long-term 2026-08-31 plus current 2026-08-31, minus cash 2026-08-31
Enterprise value TLRY
| FY May 2026 | $545.4M |
| FY May 2025 | $4.2B |
| FY May 2024 | $13.9B |
| FY May 2023 | $10.4B |
| FY May 2022 | $22.1B |
| Aug 2026 | $534.2M |
| May 2026 | $545.4M |
| Feb 2026 | $809.4M |
| Nov 2025 | $8.9B |
| Aug 2025 | $15.0B |
| May 2025 | $4.2B |
| Feb 2025 | $6.9B |
| Nov 2024 | $12.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-28.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield TLRY
| FY May 2026 | -15.9% |
| FY May 2025 | -2.9% |
| FY May 2024 | -0.4% |
| FY May 2023 | -0.1% |
| FY May 2022 | -0.9% |
| Aug 2026 | -18.8% |
| May 2026 | -15.9% |
| Feb 2026 | -8.5% |
| Nov 2025 | -0.7% |
| Aug 2025 | -0.6% |
| May 2025 | -2.9% |
| Feb 2025 | -1.3% |
| Nov 2024 | -0.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TLRY
| FY May 2026 | n/a |
| FY May 2025 | n/a |
| FY May 2024 | n/a |
| FY May 2023 | n/a |
| FY May 2022 | n/a |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-05 | 2025-12 | 2025-05 | 2024-05 | |
|---|---|---|---|---|
| Revenue | $915.5M | n/a | $821.3M | $788.9M |
| Gross profit | $260.4M | n/a | $240.6M | $223.4M |
| Operating income | -$63.0M | n/a | -$2.3B | -$174.7M |
| Net income | -$121.4M | n/a | -$2.2B | -$245.0M |
| EPS (diluted) | -1.09 | n/a | -24.56 | -3.30 |
| Operating cash flow | -$69.1M | n/a | -$94.6M | -$30.9M |
| Cash | $226.0M | $221.7M | $221.7M | $228.3M |
| Long-term debt | $120.4M | $86.4M | $86.4M | $129.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
TLRY Stock Sonar score 6/7 axes
Find similar shapesCompareTLRY ranks highest on insider conviction (81st percentile) and profitability (79th), and lowest on risk and compliance (42nd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TLRY filings, in plain words
Are Tilray Brands insiders buying or selling TLRY?
In the 180 days to 2026-10-28, Tilray Brands insiders were net buyers, a net $69.2K across purchases and sales reported on Form 4, by 3 buyers.
Read the full summary
In the 180 days to 2026-10-28, Tilray Brands insiders were net buyers of TLRY, a net $69.2K across purchases and sales reported on Form 4 by 3 buyers. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
